https://orcid.org/0000-0001-9641-1207
References
- Kanzaki T, Miwa N, Kobayashi T, Ogawa S. Eruptive pruritic papular porokeratosis. J Dermatol. 1992;19(2):109–112. doi:10.1111/j.1346-8138.1992.tb03190.x
- Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693–707. doi:10.1007/s40257-021-00618-3
- Hashimoto T, Moriyama Y, Satoh T. Linear porokeratosis with severe itch accompanied by lesional upregulation of interleukin 31, thymic stromal lymphopoietin, and periostin. Eur J Dermatol. 2021;31(4):570–572. doi:10.1684/ejd.2021.4083
- Awatani K, Hashimoto T, Satoh T. Eruptive pruritic papular porokeratosis accompanied by eosinophilic and basophilic infiltrate with upregulation of epidermal CCL26/eotaxin-3 and thymic stromal lymphopoietin. J Dermatol. 2021;48(8):e382–e383. doi:10.1111/1346-8138.15949
- Furue M. Regulation of skin barrier function via competition between AHR axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis. J Clin Med. 2020;9(11):3741. doi:10.3390/jcm9113741
- Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–1379. doi:10.1001/jamadermatol.2019.2855
- Mu X, Li W, Zhang M, et al. Successful treatment of eruptive pruritic papular porokeratosis in the elderly with tofacitinib: a case report. Clin Cosmet Investig Dermatol. 2023;16:1741–1747. doi:10.2147/CCID.S412495
- Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14(5):1001. doi:10.3390/pharmaceutics14051001
- Akada H, Akada S, Hutchison RE, Sakamoto K, Wagner KU, Mohi G. Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells. Stem Cells. 2014;32(7):1878–1889. doi:10.1002/stem.1711
- Li Y, Jiang Y, Sun J. Improvement of Hailey-Hailey disease with abrocitinib. Clin Exp Dermatol. 2023;48(5):532–533. doi:10.1093/ced/llad023
- Bao C, Xu Q, Xiao Z, et al. Abrocitinib as a novel treatment for lichen sclerosus. Br J Dermatol. 2023;189(1):136–138. doi:10.1093/bjd/ljad129
- Bai J, Su W, Fang H, Qiao J. Treatment of primary cutaneous lichenoid amyloidosis with abrocitinib: a pilot study in two cases. Int J Dermatol. 2023. doi:10.1111/ijd.16698
- Solimani F, Mesas-Fernández A, Dilling A, et al. The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus. J Eur Acad Dermatol Venereol. 2023;37. doi:10.1111/jdv.19069
- Vander Does A, Yosipovitch G. Failure of dupilimab with severe prurigo nodularis that responded well to abrocitinib. Dermatitis. 2023. doi:10.1089/derm.2022.0065